Saltar al contenido
Merck

Astrocytes expressing Vitamin D-activating enzyme identify Parkinson's disease.

CNS neuroscience & therapeutics (2022-02-16)
Samanta Mazzetti, Michela Barichella, Federica Giampietro, Angelica Giana, Alessandra M Calogero, Alida Amadeo, Nicola Palazzi, Alessandro Comincini, Giorgio Giaccone, Manuela Bramerio, Serena Caronni, Viviana Cereda, Emanuele Cereda, Graziella Cappelletti, Chiara Rolando, Gianni Pezzoli
RESUMEN

Astrocytes are involved in Parkinson's disease (PD) where they could contribute to α-Synuclein pathology but also to neuroprotection via α-Synuclein clearance. The molecular signature underlying their dual role is still elusive. Given that vitamin D has been recently suggested to be protective in neurodegeneration, the aim of our study was to investigate astrocyte and neuron vitamin D pathway alterations and their correlation with α-Synuclein aggregates (ie, oligomers and fibrils) in human brain obtained from PD patients. The expression of vitamin D pathway components CYP27B1, CYP24A1, and VDR was examined in brains obtained from PD patients (Braak stage 6; n = 9) and control subjects (n = 4). We also exploited proximity ligation assay to identified toxic α-Synuclein oligomers in human astrocytes. We found that vitamin D-activating enzyme CYP27B1 identified a subpopulation of astrocytes exclusively in PD patients. CYP27B1 positive astrocytes could display neuroprotective features as they sequester α-Synuclein oligomers and are associated with Lewy body negative neurons. The presence of CYP27B1 astrocytes distinguishes PD patients and suggests their contribution to protect neurons and to ameliorate neuropathological traits.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anticuerpo anti-apolipoproteína E., serum, Chemicon®
Sigma-Aldrich
Anti-CYP27B1 Antibody, from rabbit, purified by affinity chromatography